Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 10/08

20080262197 - Methods and materials for treating inflammatory conditions: The invention provides methods and materials for treating inflammatory conditions. Specifically, the invention provides polypeptides, isolated nucleic acids, host cells, and methods that can be used to induce an antibody response in a mammal against an antigen such as C5 or C5a. For example, the methods and materials described herein... Agent: Fish & Richardson P.C.

20080262198 - Cross-linkable glycoproteins and methods of making the same: Non-naturally occurring peptides/polypeptides/proteins comprising the crosslinking motif, Tyr-X-Tyr, wherein X is any amino acid, and methods of preparing the same.... Agent: Hahn Loeser & Parks, LLP

20080262199 - Protein kinase c peptides for use in withdrawal: A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance.... Agent: Perkins Coie LLP

20080262200 - Triazole macrocycle systems: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.... Agent: Wilson Sonsini Goodrich & Rosati

20080262201 - Method and a system for predicting protein functional site, a method for improving protein function, and a function-modified protein: The present application provides a method for predicting the functional site of a protein using data of the entire proteins of an organism of which genome data or cDNA data is known. More specifically, the present application provides a method for predicting a protein functional site, comprising the steps of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080262202 - Novel cancer-associated genes: The present invention is related to a DNA comprising a nucleotide sequence encoding a polypeptide represented by SEQ ID NO:1 or SEQ ID NO:2. The DNA according to the present invention is highly expressed in prostatic adenocarcinoma and ovarian carcinoma, and is a cancer-associated gene, so that it is possible... Agent: Birch Stewart Kolasch & Birch

20080262203 - Novel compounds: The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080262204 - Recombinant antibodies for the detection and neutralization of anthrax toxin: A composition and method for treating a host having or at risk of infection by Bacillus anthracis using an affinity matured antibody or portion thereof derived from a monoclonal antibody.... Agent: Fulbright & Jaworski L.L.P.

20080262205 - Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules... Agent: Ropes & Gray LLP

20080262206 - Method of isolating proteon nucleation centers from blood and other biological materials: Compositions and methods for the isolation and manipulation of misfolded, or partially misfolded, proteins present in blood and other biological materials are provided. In one aspect of the invention, the compositions, hereinafter termed “proteons” are comprised of misfolded proteins. Also provided are compositions and methods for the isolation and manipulation... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080262207 - Benzimidazole compounds and their use as chromatographic ligands: The present invention provides a new method for isolation and/or purification of immunoglobulins from a solution containing one or more immunoglobulins using a solid phase matrix represented by the formula: M-SP-L, wherein M is designates a matrix backbone, SP designates a spacer and L designates a substituted benzimidazole ligand.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080262197 - Methods and materials for treating inflammatory conditions: The invention provides methods and materials for treating inflammatory conditions. Specifically, the invention provides polypeptides, isolated nucleic acids, host cells, and methods that can be used to induce an antibody response in a mammal against an antigen such as C5 or C5a. For example, the methods and materials described herein... Agent: Fish & Richardson P.C.

20080262198 - Cross-linkable glycoproteins and methods of making the same: Non-naturally occurring peptides/polypeptides/proteins comprising the crosslinking motif, Tyr-X-Tyr, wherein X is any amino acid, and methods of preparing the same.... Agent: Hahn Loeser & Parks, LLP

20080262199 - Protein kinase c peptides for use in withdrawal: A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance.... Agent: Perkins Coie LLP

20080262200 - Triazole macrocycle systems: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.... Agent: Wilson Sonsini Goodrich & Rosati

20080262201 - Method and a system for predicting protein functional site, a method for improving protein function, and a function-modified protein: The present application provides a method for predicting the functional site of a protein using data of the entire proteins of an organism of which genome data or cDNA data is known. More specifically, the present application provides a method for predicting a protein functional site, comprising the steps of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080262202 - Novel cancer-associated genes: The present invention is related to a DNA comprising a nucleotide sequence encoding a polypeptide represented by SEQ ID NO:1 or SEQ ID NO:2. The DNA according to the present invention is highly expressed in prostatic adenocarcinoma and ovarian carcinoma, and is a cancer-associated gene, so that it is possible... Agent: Birch Stewart Kolasch & Birch

20080262203 - Novel compounds: The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080262204 - Recombinant antibodies for the detection and neutralization of anthrax toxin: A composition and method for treating a host having or at risk of infection by Bacillus anthracis using an affinity matured antibody or portion thereof derived from a monoclonal antibody.... Agent: Fulbright & Jaworski L.L.P.

20080262205 - Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules... Agent: Ropes & Gray LLP

20080262206 - Method of isolating proteon nucleation centers from blood and other biological materials: Compositions and methods for the isolation and manipulation of misfolded, or partially misfolded, proteins present in blood and other biological materials are provided. In one aspect of the invention, the compositions, hereinafter termed “proteons” are comprised of misfolded proteins. Also provided are compositions and methods for the isolation and manipulation... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080262207 - Benzimidazole compounds and their use as chromatographic ligands: The present invention provides a new method for isolation and/or purification of immunoglobulins from a solution containing one or more immunoglobulins using a solid phase matrix represented by the formula: M-SP-L, wherein M is designates a matrix backbone, SP designates a spacer and L designates a substituted benzimidazole ligand.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080255340 - Angiogenin complexes (angex) and uses thereof: Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by non-covalent immobilization on a naturally occurring substrate, such as a protein, lipid, nucleic acid or nucleotide substrate, are disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20080255339 - Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities: The present invention relates to chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. In particular, the invention is illustrated by examples of chimeric proteins including recombinant chimeric proteins between a gonadoptropin releasing hormone (GnRH) and an apoptosis-inducing moiety, such as a pro-apoptotic member of Bcl-2 family, such as Bik, Bax... Agent: Volpe And Koenig, P.C.

20080255341 - Assay method for group transfer reactions: The present invention relates to methods for detecting, quantifying and high throughput screening of donor-products and the catalytic activities generating the donor-products in group-transfer reactions. The invention further provides immunoassays, antibodies and kits that may be used to practice the methods of the invention.... Agent: Quarles & Brady LLP

20080255343 - Chimeric antibodies: The present invention provides a chimeric antibody or an antigen-binding portion thereof. The antigen-binding portion comprises at least two complementarity determining regions (CDR) and at least three framework regions, wherein at least one CDR is a New World primate CDR... Agent: Morrison & Foerster LLP

20080255342 - Protein purification method: e

20080255344 - Immuno-adsorbers for treatment of inflammations: The invention relates to an immunological adsorber for treating inflammations, in particular for eliminating complement factors, and, optionally, additional sepsis-mediators, such as, TNF and interleukins from body fluids. The invention also relates to a method for the production and use of said immunological adsorber. The aim of the invention is... Agent: Buchanan Ingersoll & Rooney

20080249283 - Hla-binding peptides, precursors thereof, dna fragments and recombinant vectors that code for those peptide sequences: An HLA-binding peptide binding to an HLA-A type molecule, said HLA-binding peptide comprising at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 183, and not less than 8 and not more than 11 amino acid residues is provided. Any of... Agent: Sughrue Mion, PLLC

20080249284 - Gene encoding labyrinthin, a marker for cancer: A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with... Agent: Barnes & Thornburg LLP

20080249285 - Method for affinity purification: The invention relates to a method of immunoaffinity purification which comprises the use of a binding agent which binds to an epitope that it is present at least twice on the target molecule. In another embodiment the method uses at least two different binding agents, each binding to different epitopes... Agent: Morgan Lewis & Bockius LLP

20080249286 - High-pressure refolding of proteins in the presence of binding partners: Methods for producing biologically active protein from aggregated and/or denatured proteins which comprise subjecting the protein to high hydrostatic pressure in the presence of a ligand or specific binding agent are disclosed. The ligand can be a macromolecule, such as another protein, a nucleic acid, or other macromolecules, or the... Agent: Morrison & Foerster LLP

20080249288 - Methods for chemically synthesizing immunoglobulin chimeric proteins: The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080249287 - Refolding transforming growth factor beta family proteins: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.... Agent: Fish & Richardson P.C.

20080249289 - Manufacture of a chromatography matrix: The present invention relates to method of manufacturing a sulphonate-functionalized (S-functionalized) cation exchanger, which method comprises reacting olefinic groups with bisulphite in the presence of at least one amine oxide, such as N-methyl morpholine oxide (NMO). The olefinic groups of the carrier may be allyl groups; which may be provided... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20080242834 - Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products: Proteins with Hyp-glycosylation are more likely to be secreted in plant cells at high levels than those without. Methods are disclosed for the prediction of Pro-hydroxylation and Hyp-glycosylationsites in proteins. Such methods can be used to identify (1) proteins which, without modification, are predisposed to develop Hyp-glycosylation, if expressed in... Agent: Wood, Herron & Evans, LLP

20080242835 - Ring-closing metathesis process for the preparation of macrocyclic peptides: Disclosed is a process for preparing a compound of formula (I) by protecting the secondary amide nitrogen atom in the compound of formula (III) to obtain (IV) wherein PGN is a suitable nitrogen protecting group, ring-closing the compound of formula (IV) by cyclizing it in the presence of a suitable... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080242836 - Convergent solid phase peptide synthesis by reaction of two fragments bound to solid support: A process for preparing a peptide or protein by solid phase synthesis comprising combining a sequence including one or more amino acids obtainable by C-N synthesis linked to a first resin, with an amino acid sequence including one or more amino acid obtainable by N-C synthesis linked to a second... Agent: Steptoe & Johnson LLP

20080242837 - Peptide compositions: Described are treatments of disease wherein a gene-regulatory peptide as provided herein is useful as a modulator of NF-kappaB. Also described is a pharmaceutical composition for topical application comprising a gene-regulatory peptide or functional analogue thereof, wherein the peptide or analogue modulates translocation and/or activity of a gene transcription factor.... Agent: Trask Britt

20080242838 - Labeling reagent and methods of use: The present invention provides compounds which are useful as multifunctional labels in proteomics studies. The labels of the present invention are both lysine specific and increase the overall sequence coverage obtained in polypeptide mapping experiments, by for example, increasing the ionization efficiencies of lysine-terminated tryptic fragments. In certain aspects, the... Agent: Genomics Institute Of The Novartis Research Foundation

20080242839 - Human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20080242841 - Methods of modulating cold sensory perception: The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods... Agent: Townsend And Townsend And Crew, LLP

20080242840 - Novel inhibitors of angiogenesis and tumor growth: This invention provides for polypeptides that have surprising anti-angiogenic activity. These peptides are derived from Saposin B, a previously known protein involved in the hydrolysis of sphingolipids. In addition, methods of treating mammals with these anti-angiogenic polypeptides are provided, as well as the pharmaceutical compositions used to treat. Furthermore, the... Agent: Hogan & Hartson L.L.P.

20080242842 - Decolorization/deodorization of corn zein products: Decolorized and/or deodorized zein from corn products may be recovered in high yields using zeolite adsorbents. A solution of a zein-containing corn product in an aqueous alcohol solvent is contacted with a zeolite adsorbent under conditions effective for adsorption of color and odor impurities in the corn product onto the... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20080242843 - Function of a haptoglobin-haemoglobin receptor and the uses thereof: The present invention relates to haptoglobin-haemoglobin (Hp-Hb) complex or a part thereof or a mimic thereof being operably linked to a substance and capable of binding a CD163 receptor. Furthermore, the invention relates to a CD163 variant, membrane bound or soluble, capable of binding at least one haptoglobin-haemoglobin (Hp-Hb) complex,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080242844 - Ultra-high yield intravenous immune globulin preparation: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs one or more salts from a group of salts comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride... Agent: Fish & Associates, PC Robert D. Fish

20080242845 - Fc variants with optimized properties: The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties.... Agent: Morgan, Lewis & Bockius, LLP

20080242846 - O-linked glycosylation of peptides: The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue... Agent: Morgan, Lewis & Bockius LLP (sf)

20080242847 - Position dependent recognition of gnn nucleotide triplets by zinc fingers: The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid... Agent: Robins & Pasternak

20080242848 - Commercial production of insulin and insulin-like proteins in plants: Plants are engineered to express proinsulin or insulin. The plants can be used as a source of the protein for a variety of purposes. Plant tissue can be orally administered to animals to replace the necessity of injection of insulin. Alternatively, the protein can be extracted from plant tissue and... Agent: Patricia A. Sweeney